

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2010; month=4; day=20; hr=12; min=29; sec=7; ms=854;]

=====

Application No: 10535351

Version No: 2.0

Input Set:

Output Set:

Started: 2010-04-12 17:44:26.788

Finished: 2010-04-12 17:44:31.106

Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 318 ms

Total Warnings: 54

Total Errors: 16

No. of SeqIDs Defined: 54

Actual SeqID Count: 54

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2010-04-12 17:44:26.788
Finished: 2010-04-12 17:44:31.106
Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 318 ms
Total Warnings: 54
Total Errors: 16
No. of SeqIDs Defined: 54
Actual SeqID Count: 54

Error code	Error Description
	This error has occurred more than 20 times, will not be displayed
E 257	Invalid sequence data feature in <221> in SEQ ID (36)
E 257	Invalid sequence data feature in <221> in SEQ ID (37)
E 257	Invalid sequence data feature in <221> in SEQ ID (38)
E 257	Invalid sequence data feature in <221> in SEQ ID (39)
E 257	Invalid sequence data feature in <221> in SEQ ID (40)
E 257	Invalid sequence data feature in <221> in SEQ ID (41)
E 257	Invalid sequence data feature in <221> in SEQ ID (42)
E 257	Invalid sequence data feature in <221> in SEQ ID (43)
E 257	Invalid sequence data feature in <221> in SEQ ID (45)
E 257	Invalid sequence data feature in <221> in SEQ ID (46)
E 257	Invalid sequence data feature in <221> in SEQ ID (47)
E 257	Invalid sequence data feature in <221> in SEQ ID (48)
E 257	Invalid sequence data feature in <221> in SEQ ID (49)
E 257	Invalid sequence data feature in <221> in SEQ ID (50)
E 257	Invalid sequence data feature in <221> in SEQ ID (51)
E 257	Invalid sequence data feature in <221> in SEQ ID (53)

SEQUENCE LISTING

<110> The Johns Hopkins University
Denmead, Samuel
Isaacs, John
Lilja, Hans

<120> Activation of Peptide Prodrugs by hk2

<130> 50562-P001US

<140> 10535351

<141> 2010-04-12

<150> PCT/US03/36880

<151> 2003-11-18

<150> 60/427,309

<151> 2002-11-18

<160> 54

<170> PatentIn version 3.5

<210> 1

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 1

Gly Lys Ala Arg Ala Phe

1 5

<210> 2

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 2

Gly Lys Ala Val Arg Gln

1 5

<210> 3

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 3

Gly Lys Ala Tyr Phe Met

1 5

<210> 4

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 4

Gly Lys Ala Glu Lys Val

1 5

<210> 5

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 5

Gly Lys Ala Phe Arg Lys

1 5

<210> 6

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 6

Gly Lys Ala Lys Pro Arg

1 5

<210> 7

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 7

Gly Lys Ala Ala Tyr Tyr
1 5

<210> 8

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 8

Gly Lys Ala Trp Tyr His
1 5

<210> 9

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 9

Gly Lys Ala Phe Arg Arg
1 5

<210> 10

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 10

Gly Lys Ala Ile Gln Arg
1 5

<210> 11

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 11

Gly Lys Ala Met Arg Gln
1 5

<210> 12

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 12

Gly Lys Ala Ala Leu Met
1 5

<210> 13

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 13

Gly Lys Ala Gln Gly Phe
1 5

<210> 14

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 14

Gly Lys Ala Asn Met Asn
1 5

<210> 15

<211> 5

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 15

Leu Ile Gln Ser Arg
1 5

<210> 16

<211> 5

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 16

Asp Asp Asp Asp Lys
1 5

<210> 17

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> misc_feature

<222> (4)..(6)

<223> X is any amino acid

<400> 17

Gly Lys Ala Xaa Xaa Xaa
1 5

<210> 18

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is acetylated 3-nitrotyrosine

<220>

<221> MISC_FEATURE

<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 18

Xaa Gly Lys Ala Phe Arg Arg Leu Gly Xaa
1 5 10

<210> 19
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 19

Gly Ser Lys Gly His Phe Arg Leu
1 5

<210> 20
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 20

Gly Ser Lys Gly His Phe His Leu
1 5

<210> 21
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 21

Xaa Gly Lys Ala Phe Arg Arg Leu Gly Xaa
1 5 10

<210> 22
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 22

Gly Lys Ala Arg Ala Phe Leu
1 5

<210> 23
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 23

Gly Lys Ala Val Arg Gln Leu
1 5

<210> 24
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 24

Gly Lys Ala Tyr Phe Met Leu
1 5

<210> 25
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 25

Gly Lys Ala Glu Lys Val Leu
1 5

<210> 26
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 26

Gly Lys Ala Phe Arg Lys Leu
1 5

<210> 27
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 27

Gly Lys Ala Lys Pro Arg Leu
1 5

<210> 28
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 28

Gly Lys Ala Ala Tyr Tyr Leu
1 5

<210> 29
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 29

Gly Lys Ala Trp Tyr His Leu

1 5

<210> 30
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 30

Gly Lys Ala Phe Arg Arg Leu
1 5

<210> 31
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 31

Gly Lys Ala Ile Gln Arg Leu
1 5

<210> 32
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 32

Gly Lys Ala Met Arg Gln Leu
1 5

<210> 33
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 33

Gly Lys Ala Ala Leu Met Leu
1 5

<210> 34
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 34

Gly Lys Ala Gln Gly Phe Leu
1 5

<210> 35
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<400> 35

Gly Lys Ala Asn Met Asn Leu
1 5

<210> 36
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 36

Xaa Gly Lys Ala Arg Ala Phe Xaa Phe Xaa

1 5 10

<210> 37
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 37

Xaa Gly Lys Ala Lys Pro Arg Xaa Phe Xaa
1 5 10

<210> 38
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 38

Xaa Gly Lys Ala Phe Arg Arg Xaa Phe Xaa
1 5 10

<210> 39

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is 3-nitrotyrosine

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Dpr

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X is 2-aminobenzoic acid-substituted Lysine (Lys-Abz)

<400> 39

Xaa Gly Lys Ala Met Arg Gln Xaa Phe Xaa
1 5 10

<210> 40

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is 3-nitrotyrosine

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Dpr

<220>

<221> MISC_FEATURE

<222> (12)..(12)
<223> X is 2-aminobenzoic acid substituted lysine (Lys-Abz)

<400> 40

Xaa Gly Ser Lys Gly His Phe Lys Leu Xaa Phe Xaa
1 5 10

<210> 41
<211> 7
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is leucine functionalized at the C-terminal end with 12ADT
(L12ADT).

<400> 41

Gly Lys Ala Phe Arg Arg Xaa
1 5

<210> 42
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)

<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 42

Xaa Gly Lys Ala Phe Arg Arg Xaa Gly Xaa
1 5 10

<210> 43

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<400> 43

Gly Lys Ala Phe Arg Arg Leu Gly
1 5

<210> 44

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> X is leucine C-terminal functionalized with 12ADT (L12ADT)

<400> 44

Gly Lys Ala Phe Arg Arg Xaa
1 5

<210> 45

<211> 11

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is 3-nitrotyrosine

 <220>
 <221> MOD_RES
 <222> (10)..(10)
 <223> Dpr

 <220>
 <221> MISC_FEATURE
 <222> (11)..(11)
 <223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 45

Xaa Gly Ser Lys Gly His Phe Lys Leu Xaa Xaa
 1 5 10

<210> 46
 <211> 11
 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is 3-nitrotyrosine

<220>
 <221> MOD_RES
 <222> (10)..(10)
 <223> Dpr

<220>
 <221> MISC_FEATURE
 <222> (11)..(11)
 <223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 46

Xaa Gly Ser Lys Gly Pro Phe Lys Leu Xaa Xaa
 1 5 10

<210> 47
 <211> 11
 <212> PRT
 <213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is 3-nitrotyrosine

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Dpr

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 47

Xaa Gly Ser Lys Gly His Phe His Leu Xaa Xaa

1 5 10

<210> 48

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is 3-nitrotyrosine

<220>

<221> MISC_FEATURE

<222> (5)..(7)

<223> X is any L-amino acid except cysteine

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Dpr

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 48

Xaa Gly Lys Ala Xaa Xaa Xaa Xaa Phe Xaa

1 5 10

<210> 49
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MISC_FEATURE
<222> (5)..(7)
<223> X is any L-amino acid except cysteine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid substituted lysine bound to a solid
phase PEGA support

<400> 49

Xaa Gly Lys Ala Xaa Xaa Xaa Xaa Phe Xaa
1 5 10

<210> 50
<211> 6
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is any natural amino acid except cysteine protected with an
FMOC group

<220>
<221> MISC_FEATURE
<222> (2)..(3)
<223> X is any natural amino acid except cysteine

<220>

<221> MOD_RES

<222> (4)..(4)

<223> Dpr

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz) bound to a
PEGA solid support

<400> 50

Xaa Xaa Xaa Xaa Phe Xaa

1 5

<210> 51

<211> 7

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X is lysine protected with a side-chain ivDde protecting group

<400> 51

Gly Xaa Ala Phe Arg Arg Leu

1 5

<210> 52

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is 3-nitrotyrosine

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is 2-aminobenzoic acid substituted lysine (Lys-Abz) attached to
a PEGA solid support

<400> 52

Xaa Gly Lys Ala Phe Arg Leu Xaa
1 5

<210> 53
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is 3-nitrotyrosine

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Dpr

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is 2-aminobenzoic acid-substituted lysine attached to a PEGA
solid phase support

<400> 53

Xaa Gly Lys Ala Phe Arg Leu Xaa Phe Xaa
1 5 10

<210> 54
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is glycine N-terminal bound to a 2-aminobenzoic acid group
(Abz)

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X is 3-nitrotyrosine

<400> 54

Xaa Lys Ala Phe Arg Arg Leu Xaa

1 5